[go: up one dir, main page]

CA2981285A1 - Compositions et methodes de traitement de troubles epileptiques - Google Patents

Compositions et methodes de traitement de troubles epileptiques Download PDF

Info

Publication number
CA2981285A1
CA2981285A1 CA2981285A CA2981285A CA2981285A1 CA 2981285 A1 CA2981285 A1 CA 2981285A1 CA 2981285 A CA2981285 A CA 2981285A CA 2981285 A CA2981285 A CA 2981285A CA 2981285 A1 CA2981285 A1 CA 2981285A1
Authority
CA
Canada
Prior art keywords
naed
cbd
composition
fatty acid
lipophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2981285A
Other languages
English (en)
Inventor
Ramachandra MUKUNDA
Ranga Chelva Krishna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGC Pharma Inc
Original Assignee
India Globalization Capital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by India Globalization Capital Inc filed Critical India Globalization Capital Inc
Publication of CA2981285A1 publication Critical patent/CA2981285A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des méthodes de traitement de troubles épileptiques, tels que l'épilepsie chez l'homme et l'animal au moyen de la combinaison d'un médicament anti-épileptique non-barbiturique (NAED), de cannabidiol phytocannabinoïde (CBD); et d'un acide gras lipophile tel qu'un acide alpha-linolénique (ALA)
CA2981285A 2015-04-01 2016-03-25 Compositions et methodes de traitement de troubles epileptiques Abandoned CA2981285A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562141438P 2015-04-01 2015-04-01
US62/141,438 2015-04-01
PCT/US2016/024145 WO2016160542A1 (fr) 2015-04-01 2016-03-25 Compositions et méthodes de traitement de troubles épileptiques

Publications (1)

Publication Number Publication Date
CA2981285A1 true CA2981285A1 (fr) 2016-10-06

Family

ID=57007479

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2981285A Abandoned CA2981285A1 (fr) 2015-04-01 2016-03-25 Compositions et methodes de traitement de troubles epileptiques

Country Status (2)

Country Link
CA (1) CA2981285A1 (fr)
WO (1) WO2016160542A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044370A1 (fr) 2014-09-16 2016-03-24 India Globalization Capital, Inc. Composition cannabinoïde et méthode de traitement de la douleur
CA2974895A1 (fr) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Compositions et procedes de traitement de troubles epileptiques
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
WO2017218629A1 (fr) * 2016-06-15 2017-12-21 India Globalization Capital, Inc. Méthode et composition pour traiter des troubles epileptiques
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CA3089994A1 (fr) 2018-01-31 2019-08-08 Canopy Holdings, LLC Poudre de chanvre
EP3773527A4 (fr) 2018-03-30 2022-04-13 India Globalization Capital, Inc. Méthode et composition de traitement de troubles du snc
WO2020077153A1 (fr) 2018-10-10 2020-04-16 Canopy Holdings, LLC Synthèse du cannabigérol
GB2601755A (en) 2020-12-08 2022-06-15 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007253814A1 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US20080254017A1 (en) * 2006-06-19 2008-10-16 Bodybio, Inc. Methods and compositions for treating symptomes of diseases related to imbalance of essential fatty acids
WO2010048423A1 (fr) * 2008-10-24 2010-04-29 Ark Diagnostics, Inc. Immunodosages du lévétiracétam
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
WO2011063164A2 (fr) * 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Médicaments de cannabinoïde à libération prolongée
EP3049076A4 (fr) * 2013-09-26 2018-04-18 Ronald D. Sekura Traitements topiques comprenant un produit médicamenteux botanique dérivé du cannabis sp.
US10052339B2 (en) * 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy

Also Published As

Publication number Publication date
WO2016160542A1 (fr) 2016-10-06

Similar Documents

Publication Publication Date Title
CA2981285A1 (fr) Compositions et methodes de traitement de troubles epileptiques
US10751300B2 (en) Composition and method for treating seizure disorders
US12023305B2 (en) Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
US12121499B2 (en) Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US11351152B2 (en) Method and composition for treating seizure disorders
CA2961410C (fr) Composition cannabinoide et methode de traitement de la douleur
WO2022017909A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à des syndromes d'épilepsies rares associées à des anomalies structurales du cerveau
Babayeva et al. Marijuana compounds: a non-conventional therapeutic approach to epilepsy in children
WO2022017950A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à la sclérose temporale mésiale bilatérale
WO2022017922A1 (fr) Utilisation de cannabidiol dans le traitement de crises associées à un syndrome auriculo-temporal
Babayeva et al. Marijuana Compounds: A Non-Conventional Therapeutic Approach to Epilepsy in Children. J Addict Neuropharmacol 1: 002

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210105

EEER Examination request

Effective date: 20210105

FZDE Discontinued

Effective date: 20230802